Medtronic Reports Q3 GAAP EPS Decline Amid Restructuring & Faces $1.1B+ Antitrust Verdict
MDT sits 22% above its 52-week low of $79.55.
Summary
Medtronic plc reported an 11.9% decline in Q3 GAAP diluted EPS, driven by increased tariffs and restructuring charges, despite strong revenue growth. The company also faces a significant potential liability from a $382 million antitrust jury verdict, which could be trebled.
Key Events · Earnings and Guidance · MDT
-
Q3 GAAP EPS Decline
Diluted EPS decreased by 11.9% to $0.89 for the quarter, contrasting with earlier positive non-GAAP guidance, primarily due to increased tariffs and restructuring charges.
-
Significant Antitrust Verdict
A jury awarded $382 million in damages in an antitrust lawsuit, which will be trebled, creating a potential liability exceeding $1.1 billion. Medtronic plans to appeal the verdict.
-
Increased Restructuring Charges
The company incurred $172 million in restructuring charges for the quarter, including $84 million in asset write-offs, partly related to the planned Diabetes business separation.
-
Strong Revenue Growth
Net sales for the quarter increased by 8.7% to $9.017 billion, driven by growth across most businesses and favorable currency impacts.
Analysis · MDT · Industrial Applications And Services
This 10-Q provides the full financial details for the third quarter of fiscal year 2026, adding crucial context to the preliminary "strong financial results" announced in the 8-K on February 17, 2026. While net sales increased by 8.7% for the quarter, GAAP diluted EPS decreased by 11.9% year-over-year. This decline was primarily attributed to higher costs from tariffs on imported goods and $172 million in restructuring charges, including $84 million in asset write-offs related to terminating a manufacturing agreement in the Diabetes unit. The most significant new development is a jury verdict against Medtronic in an antitrust lawsuit, awarding $382 million in damages, which will be automatically trebled to over $1.1 billion. Although Medtronic plans to challenge this verdict and has not yet accrued a liability, this represents a substantial potential financial risk. On a positive note, the company announced its intent to acquire CathWorks Ltd. for up to $585 million, expanding its Cardiovascular portfolio, and the U.S. Supreme Court ruled President Trump's tariff policies unconstitutional, which could alleviate future cost pressures.
At the time of this filing, MDT was trading at $96.75 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $124B. The 52-week trading range was $79.55 to $106.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.